Interferon beta1a therapy changes lipoprotein metabolism in patients with multiple sclerosis

Clin Chem Lab Med. 2000 Mar;38(3):209-13. doi: 10.1515/CCLM.2000.030.


To assess whether interferon beta1a (IFNbeta1a) therapy affects plasma lipoprotein metabolism, twelve patients with relapsing-remitting multiple sclerosis (MS) were studied during a two-year follow-up period. High density lipoprotein (HDL2) cholesterol and the HDL2/HDL3 ratio were increased at year 2 and lipoprotein (a) was transitorily increased at year 1, in comparison to baseline levels. Apolipoprotein A-I was lower and apolipoprotein E higher at year 1, only in a subgroup of patients who experienced relapses and/or progressed during therapy. These findings suggest that IFNbeta1a treatment is associated with changes in the lipoprotein metabolism. Alterations in this metabolism could be related to the immunomodulatory actions of the drug and the disease activity in multiple sclerosis patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Apolipoprotein A-I / blood
  • Female
  • Follow-Up Studies
  • Humans
  • Interferon beta-1a
  • Interferon-beta / therapeutic use*
  • Lipoproteins / blood*
  • Lipoproteins, HDL / blood
  • Lipoproteins, HDL2
  • Lipoproteins, HDL3
  • Male
  • Middle Aged
  • Multiple Sclerosis / blood*
  • Multiple Sclerosis / drug therapy*
  • Recurrence
  • Time Factors


  • Apolipoprotein A-I
  • Lipoproteins
  • Lipoproteins, HDL
  • Lipoproteins, HDL2
  • Lipoproteins, HDL3
  • Interferon-beta
  • Interferon beta-1a